Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1513243

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1513243

Retinoblastoma Treatment Global Market Report 2024

PUBLISHED:
PAGES: 175 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

Retinoblastoma treatment encompasses medical interventions and therapies directed at diagnosing, managing, and potentially curing retinoblastoma, a rare type of eye cancer predominantly found in young children, typically before the age of five. The primary objective of retinoblastoma treatment is to eliminate or control the cancerous growths within the eye(s) while preserving vision and minimizing the risk of metastasis or recurrence.

The main types of retinoblastoma treatment include non-hereditary retinoblastoma and hereditary retinoblastoma. Non-hereditary retinoblastoma, a rare cancer affecting children under six years old, encompasses various treatment modalities such as surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, ophthalmic artery infusion chemotherapy, and high-dose chemotherapy with stem cell transplant. These treatments are applicable to both intraocular and extraocular retinoblastoma stages and are commonly administered in hospitals, cancer institutes, and other medical facilities.

The retinoblastoma treatment market research report is one of a series of new reports from The Business Research Company that provides retinoblastoma treatment market statistics, including retinoblastoma treatment industry global market size, regional shares, competitors with a retinoblastoma treatment market share, detailed retinoblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinoblastoma treatment industry. This retinoblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinoblastoma treatment market size has grown strongly in recent years. It will grow from $1.93 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The historical growth can be attributed to an increasing number of funding sources, the likelihood of retinoblastoma recurrence, early diagnosis and treatment of retinoblastoma, growing awareness regarding different types of cancers, and significant advancements in cancer research.

The retinoblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.56 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period can be attributed to the rising demand for ophthalmic treatment and surgeries, the increasing incidence of retinoblastoma, expanding research and development activities, growing awareness regarding retinoblastoma treatment, and escalating healthcare expenditure. Significant trends expected in the forecast period encompass advancements in medical technology, enhanced diagnostic capabilities, increased investments in pediatric oncology, approvals of new products, and enhancements in medical infrastructure.

The rising need for ophthalmic treatment and surgeries is anticipated to drive the expansion of the retinoblastoma treatment market in the foreseeable future. Ophthalmic treatment and surgeries encompass a range of medical interventions and procedures aimed at diagnosing, managing, and correcting disorders affecting the eyes and visual system. This demand surge is attributed to factors such as an aging population, increased prevalence of conditions such as cataracts and age-related macular degeneration, technological advancements enabling more efficient and accessible treatments, and heightened awareness leading to earlier detection and intervention. Retinoblastoma treatment is essential for ophthalmic surgeries aimed at addressing cancerous growths within the eye(s), preventing metastasis or recurrence, while also preserving vision and eye function. For example, in September 2023, a report from the UK's Office for Health Improvement and Disparities revealed over 4.09 million admissions for cataract surgery in England, with a rate of 3,803 (3,789 to 3,816) per 100,000 population in the financial year ending 2022. Additionally, there were over 10,900 admissions for rhegmatogenous retinal detachment surgeries and over 677,000 intravitreal injection therapy procedures performed during the same period, with rates of 23.4 (22.9 to 24.0) and 4,796 (4,769 to 4,823) per 100,000 population, respectively. Consequently, the rising demand for ophthalmic treatment and surgeries is propelling the growth of the retinoblastoma treatment market.

Key players in the retinoblastoma treatment market are dedicated to developing innovative solutions, such as oncolytic adenovirus, to cater to the evolving needs of customers with enhanced functionalities. An oncolytic adenovirus is a genetically modified virus designed to infect and selectively destroy cancer cells while sparing normal cells. For instance, in February 2022, VCN Biosciences, a biotechnology company based in Spain, received orphan drug designation from the U.S. Food and Drug Administration for VCN-01, a genetically engineered oncolytic adenovirus intended for retinoblastoma treatment. VCN-01's distinctive feature lies in its oncolytic adenovirus nature, which is currently undergoing clinical trials targeting cancers with no definitive cure, including pancreatic carcinoma and retinoblastoma (RB). VCN-01 has undergone scrutiny in four phase 1 clinical trials and is being investigated as a standalone treatment option for RB patients who have previously undergone unsuccessful chemotherapy. Intravitreal administration of VCN-01 has demonstrated complete remission and tumor reduction in several patients, paving the way for its orphan drug status approval.

In March 2022, Synthetic Biologics Inc., a biotechnology company based in the United States, acquired VCN Biosciences S.L. for an undisclosed sum. This acquisition represents a significant advancement in Synthetic Biologics' pipeline, integrating VCN's primary clinical-stage drug candidate, VCN-01. VCN Biosciences S.L. is a biotechnology company based in Spain specializing in retinoblastoma treatment.

Major companies operating in the retinoblastoma treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Otsuka Pharmaceutical, Daiichi Sankyo Company, Taiho Pharmaceutical Co. Ltd., Icon Bioscience Inc., Ono Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Cadila Pharmaceuticals, Arcus Biosciences Inc., Sheba Medical Center, Cellceutix Corporation, Phio Pharmaceuticals Inc.

North America was the largest region in the retinoblastoma treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinoblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinoblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinoblastoma treatment market consists of revenues earned by entities by providing services such as multidisciplinary care, genetic testing and counseling, remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinoblastoma treatment market also includes sales of targeted therapy medications, genetic testing kits and intravitreal chemotherapy injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinoblastoma Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinoblastoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinoblastoma treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinoblastoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Non-Hereditary Retinoblastoma; Hereditary Retinoblastoma
  • 2) By Treatment Type: Surgery; Radiation Therapy; Laser Therapy (Photocoagulation); Cryotherapy; Thermotherapy; Chemotherapy; Ophthalmic Artery Infusion Chemotherapy; High-Dose Chemotherapy And Stem Cell Transplant
  • 3) By Disease Stage: Intraocular Retinoblastoma; Extraocular Retinoblastoma
  • 4) By Application: Hospitals; Cancer Institutes; Other Applications
  • Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.
Product Code: r18230

Table of Contents

1. Executive Summary

2. Retinoblastoma Treatment Market Characteristics

3. Retinoblastoma Treatment Market Trends And Strategies

4. Retinoblastoma Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Retinoblastoma Treatment Market Size and Growth

  • 5.1. Global Retinoblastoma Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Retinoblastoma Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Retinoblastoma Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Retinoblastoma Treatment Market Segmentation

  • 6.1. Global Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Non-Hereditary Retinoblastoma
  • Hereditary Retinoblastoma
  • 6.2. Global Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Surgery
  • Radiation Therapy
  • Laser Therapy (Photocoagulation)
  • Cryotherapy
  • Thermotherapy
  • Chemotherapy
  • Ophthalmic Artery Infusion Chemotherapy
  • High-Dose Chemotherapy And Stem Cell Transplant
  • 6.3. Global Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Intraocular Retinoblastoma
  • Extraocular Retinoblastoma
  • 6.4. Global Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Cancer Institutes
  • Other Applications

7. Retinoblastoma Treatment Market Regional And Country Analysis

  • 7.1. Global Retinoblastoma Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Retinoblastoma Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Retinoblastoma Treatment Market

  • 8.1. Asia-Pacific Retinoblastoma Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Retinoblastoma Treatment Market

  • 9.1. China Retinoblastoma Treatment Market Overview
  • 9.2. China Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Retinoblastoma Treatment Market

  • 10.1. India Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Retinoblastoma Treatment Market

  • 11.1. Japan Retinoblastoma Treatment Market Overview
  • 11.2. Japan Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Retinoblastoma Treatment Market

  • 12.1. Australia Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Retinoblastoma Treatment Market

  • 13.1. Indonesia Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Retinoblastoma Treatment Market

  • 14.1. South Korea Retinoblastoma Treatment Market Overview
  • 14.2. South Korea Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Retinoblastoma Treatment Market

  • 15.1. Western Europe Retinoblastoma Treatment Market Overview
  • 15.2. Western Europe Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Retinoblastoma Treatment Market

  • 16.1. UK Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Retinoblastoma Treatment Market

  • 17.1. Germany Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Retinoblastoma Treatment Market

  • 18.1. France Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Retinoblastoma Treatment Market

  • 19.1. Italy Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Retinoblastoma Treatment Market

  • 20.1. Spain Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Retinoblastoma Treatment Market

  • 21.1. Eastern Europe Retinoblastoma Treatment Market Overview
  • 21.2. Eastern Europe Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Retinoblastoma Treatment Market

  • 22.1. Russia Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Retinoblastoma Treatment Market

  • 23.1. North America Retinoblastoma Treatment Market Overview
  • 23.2. North America Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Retinoblastoma Treatment Market

  • 24.1. USA Retinoblastoma Treatment Market Overview
  • 24.2. USA Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Retinoblastoma Treatment Market

  • 25.1. Canada Retinoblastoma Treatment Market Overview
  • 25.2. Canada Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Retinoblastoma Treatment Market

  • 26.1. South America Retinoblastoma Treatment Market Overview
  • 26.2. South America Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Retinoblastoma Treatment Market

  • 27.1. Brazil Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Retinoblastoma Treatment Market

  • 28.1. Middle East Retinoblastoma Treatment Market Overview
  • 28.2. Middle East Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Retinoblastoma Treatment Market

  • 29.1. Africa Retinoblastoma Treatment Market Overview
  • 29.2. Africa Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Retinoblastoma Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Retinoblastoma Treatment Market Competitive Landscape
  • 30.2. Retinoblastoma Treatment Market Company Profiles
    • 30.2.1. Johnson & Johnson Services Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi S.A.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bristol-Myers Squibb Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Retinoblastoma Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Pfizer Inc.
  • 31.3. GlaxoSmithKline Plc
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Eli Lilly and Company
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. Baxter International Inc.
  • 31.8. Regeneron Pharmaceuticals Inc.
  • 31.9. Astellas Pharma Inc.
  • 31.10. Otsuka Pharmaceutical
  • 31.11. Daiichi Sankyo Company
  • 31.12. Taiho Pharmaceutical Co. Ltd.
  • 31.13. Icon Bioscience Inc.
  • 31.14. Ono Pharmaceutical Co. Ltd.
  • 31.15. Nippon Shinyaku Co. Ltd.

32. Global Retinoblastoma Treatment Market Competitive Benchmarking

33. Global Retinoblastoma Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Retinoblastoma Treatment Market

35. Retinoblastoma Treatment Market Future Outlook and Potential Analysis

  • 35.1 Retinoblastoma Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Retinoblastoma Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Retinoblastoma Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!